The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer

The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer

In the treatment of pancreatic ductal adenocarcinoma (PDAC), comorbidities such as cachexia limit quality of life and survival. Here, the authors show TLR7/8 agonist R848 remodels host and tumour immune responses, promoting survival and attenuating cachexia in murine models of PDAC.

Guardado en:
Detalles Bibliográficos
Autores principales: Katherine A. Michaelis, Mason A. Norgard, Xinxia Zhu, Peter R. Levasseur, Shamilene Sivagnanam, Shannon M. Liudahl, Kevin G. Burfeind, Brennan Olson, Katherine R. Pelz, Diana M. Angeles Ramos, H. Carlo Maurer, Kenneth P. Olive, Lisa M. Coussens, Terry K. Morgan, Daniel L. Marks
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2019
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/32ad424ed67248b39855a6f6ea030e5f
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:In the treatment of pancreatic ductal adenocarcinoma (PDAC), comorbidities such as cachexia limit quality of life and survival. Here, the authors show TLR7/8 agonist R848 remodels host and tumour immune responses, promoting survival and attenuating cachexia in murine models of PDAC.

Ejemplares similares